Posted by Michael Wonder on 08 Nov 2023
Mitsubishi Tanabe Pharma Canada announces that Company's oral treatment formulation for amyotrophic lateral sclerosis has been added to the provincial drug plans in Prince Edward Island, Newfoundland and Labrador
7 November 2023 - Mitsubishi Tanabe Pharma Canada today announced that Radicava oral suspension (edaravone) is now covered under the Prince Edward Island Pharmacare Formulary (special authorisation) and the Newfoundland and Labrador Prescription Drug Program (special authorisation) for the treatment of people living with amyotrophic lateral sclerosis, a rapidly progressive, neurodegenerative disease.
In addition to Prince Edward Island and Newfoundland and Labrador, Radicava oral suspension, is listed on the public drug plans in Ontario, Alberta, Quebec, British Columbia, New Brunswick, Nova Scotia and Saskatchewan.
